Latest news with #Lactococcus
Time of India
20-07-2025
- Health
- Time of India
Development of indigenous multi-stage Malaria vaccine 'AdFalciVax' is underway
The Indian Council of Medical Research (ICMR), through its Regional Medical Research Centre, Bhubaneswar (RMRCBB) and National Institute of Malaria Research (NIMR), in partnership with the Department of Biotechnology-National Institute of Immunology (DBT-NII), is currently developing a novel recombinant chimeric malaria vaccine candidate, named AdFalciVax . AdFalciVax is the first indigenous recombinant chimeric malaria vaccine specifically designed to target two critical stages of Plasmodium falciparum, the parasite responsible for the most lethal form of malaria. Explore courses from Top Institutes in Select a Course Category Design Thinking Product Management others Healthcare Cybersecurity Project Management Management Data Analytics Degree PGDM Public Policy Operations Management Artificial Intelligence MBA Finance Digital Marketing Technology Data Science healthcare MCA Data Science CXO Others Leadership Skills you'll gain: Duration: 22 Weeks IIM Indore CERT-IIMI DTAI Async India Starts on undefined Get Details Skills you'll gain: Duration: 25 Weeks IIM Kozhikode CERT-IIMK PCP DTIM Async India Starts on undefined Get Details The vaccine aims to protect against human infection while also reducing vector-borne community transmission of the parasite. According to the release, the vaccine has demonstrated excellent efficacy in the preclinical stage of development. Preclinical data suggest that AdFalciVax may have advantages over existing single-stage vaccines, including broader protection by targeting two vulnerable parasite stages, lower risk of immune evasion, potential for better long-term immunity, and extended thermal stability with functionality maintained for over nine months at room temperature. AdFalciVax is a recombinant multistage vaccine produced in Lactococcus lactis, designed to protect both individual humans and reduce the community transmission cycle. Live Events It represents one of the most advanced malaria vaccine candidates globally, with a rational design targeting two key stages of the parasite. This vaccine consists of a stable and functional recombinant chimaera between antigenic components that promises dual protection. ICMR intends to license the technology for AdFalciVax to eligible organisations and manufacturers for further development, manufacture, and commercialisation under non-exclusive agreements. This approach aims to enable wider outreach and maximise public health benefits. All collaborations will adhere to ICMR's Intellectual Property Policy. As an indigenously developed vaccine candidate that fulfils the Make in India mandate, AdFalciVax holds the potential to contribute substantially to malaria eradication by preventing infection and minimising community transmission. This information is provided for awareness purposes only. The vaccine candidate is in its early research and development phases and is not yet available for any clinical use or commercialisation.
The Hindu
19-07-2025
- Health
- The Hindu
ICMR seeks collaboration for malaria vaccine production through tech transfer
Indian Council of Medical Research (ICMR), Delhi, has invited Expression of Interest (EoI) from eligible organisations, companies and manufacturers for undertaking 'Transfer of Technology' for commercialisation of 'a recombinant chimeric multi-stage malaria vaccine (AdFalciVax) against Plasmodium falciparum' useful in preventing Plasmodium falciparum infection in humans and minimizing its community transmission. The goal is to facilitate the commercialisation of this vaccine to prevent and minimize malaria transmission, and the EoI is open until August 17. The Council noted that it would provide technical support through its team of experienced scientists in study planning, product development, development of study protocol, results/data analysis, outcome assessment, safety and efficacy assessment, product improvement, etc., if deemed fit upon mutual understanding between ICMR and the collaborative company. Additionally, while the Council will have no financial implications unless otherwise specified, its Institutes would provide support and facilitation to conduct the research and development (R&D)/clinical study of new technology/product in India through its affiliates/institutes, in collaboration with the company/institutions. It would also provide technical support in development of technology/product and will also facilitate the validation, if required. 'ICMR-Regional Medical Research Centre, Bhubaneswar (ICMR-RMRCBB) is one of the four constituent institutes that has led the development of the technology and has technical-know-how of the process to produce this recombinant chimeric multi-stage malaria vaccine in Lactococcus lactis. The pre-clinical validation of this technology was conducted in collaboration with ICMR-National Institute of Malaria Research (ICMR-NIMR), another constituent institute of ICMR, and National Institute of Immunology (NII), New Delhi, an autonomous research institute of the Department of Biotechnology,' it added.
